Nicholas K Cheung1,2, Michael W Carr1, Udayan Ray3,2, Duncan McKenzie2,4, Jens J Froelich1,2. 1. Department of Medical Imaging, Neuroradiology, Royal Hobart Hospital, Hobart, Tasmania, Australia. 2. Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. 3. Department of Pathology, Royal Hobart Hospital, Hobart, Tasmania, Australia. 4. Department of Pharmacy, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Abstract
BACKGROUND: Platelet inhibitors are used to prevent thromboembolic complications related to neurovascular stenting (NVS) procedures. Despite substantial inter-individual variability of functional platelet inhibition, the value of platelet function tests (PFT) to assess inhibition remains controversial. OBJECTIVE: This study was conducted to compare differences in thromboembolic complication rates associated with NVS in platelet-inhibited patients with and without PFT. Clinical neurological outcomes were assessed by differences in the modified Rankin Scale (mRS). MATERIALS AND METHODS: One hundred seventeen consecutive patients underwent elective NVS procedures within a 7-year period. All patients received aspirin and clopidogrel 8 days before the procedure. Fifty-two patients were treated without assessment of platelet inhibition, and 65 patients were tested for clopidogrel resistance. When clopidogrel resistance was revealed, corresponding patients were converted to ticagrelor. Changes in mRS and thromboembolic event rates were compared between the 2 cohorts. RESULTS: Thirty-five percent of patients from the cohort subjected to PFT tests showed inadequate platelet inhi-bition under clopidogrel and were converted to ticagrelor. Compared to the non-PFT test -cohort, neurological deficits were significantly reduced (12 vs. 0%; p = 0.009) and a lower number of thromboembolic events was found (12 vs. 3%; p > 0.05) within the test cohort. CONCLUSION: PFT appears to identify patients with clopidogrel resistance prior to NVS procedures. When non-responders are converted to alternative platelet inhibitors, neurological outcomes and thromboembolic complication rates may improve. Consequently, this study provides preliminary evidence that PFT may be a useful clinical tool to enhance procedural safety and improve clinical outcomes in NVS procedures.
BACKGROUND: Platelet inhibitors are used to prevent thromboembolic complications related to neurovascular stenting (NVS) procedures. Despite substantial inter-individual variability of functional platelet inhibition, the value of platelet function tests (PFT) to assess inhibition remains controversial. OBJECTIVE: This study was conducted to compare differences in thromboembolic complication rates associated with NVS in platelet-inhibited patients with and without PFT. Clinical neurological outcomes were assessed by differences in the modified Rankin Scale (mRS). MATERIALS AND METHODS: One hundred seventeen consecutive patients underwent elective NVS procedures within a 7-year period. All patients received aspirin and clopidogrel 8 days before the procedure. Fifty-two patients were treated without assessment of platelet inhibition, and 65 patients were tested for clopidogrel resistance. When clopidogrel resistance was revealed, corresponding patients were converted to ticagrelor. Changes in mRS and thromboembolic event rates were compared between the 2 cohorts. RESULTS: Thirty-five percent of patients from the cohort subjected to PFT tests showed inadequate platelet inhi-bition under clopidogrel and were converted to ticagrelor. Compared to the non-PFT test -cohort, neurological deficits were significantly reduced (12 vs. 0%; p = 0.009) and a lower number of thromboembolic events was found (12 vs. 3%; p > 0.05) within the test cohort. CONCLUSION: PFT appears to identify patients with clopidogrel resistance prior to NVS procedures. When non-responders are converted to alternative platelet inhibitors, neurological outcomes and thromboembolic complication rates may improve. Consequently, this study provides preliminary evidence that PFT may be a useful clinical tool to enhance procedural safety and improve clinical outcomes in NVS procedures.
Authors: Juergen Koessler; Anna L Kobsar; Mirjana S Rajkovic; Andreas Schafer; Ulrike Flierl; Stephanie Pfoertsch; Johann Bauersachs; Udo Steigerwald; Andreas R Rechner; Ulrich Walter Journal: Platelets Date: 2010-09-27 Impact factor: 3.862
Authors: C Combescure; P Fontana; N Mallouk; P Berdague; C Labruyere; I Barazer; J C Gris; S Laporte; P Fabbro-Peray; J L Reny Journal: J Thromb Haemost Date: 2010-02-12 Impact factor: 5.824
Authors: Chirag D Gandhi; Ketan R Bulsara; Johanna Fifi; Tareq Kass-Hout; Ryan A Grant; Josser E Delgado Almandoz; Joey English; Philip M Meyers; Todd Abruzzo; Charles J Prestigiacomo; Ciaran James Powers; Seon-Kyu Lee; Barbara Albani; Huy M Do; Clifford J Eskey; Athos Patsalides; Steven Hetts; M Shazam Hussain; Sameer A Ansari; Joshua A Hirsch; Michael Kelly; Peter Rasmussen; William Mack; G Lee Pride; Michael J Alexander; Mahesh V Jayaraman Journal: J Neurointerv Surg Date: 2014-07-23 Impact factor: 5.836
Authors: Abbie Edwards; Joseph A Jakubowski; Andreas R Rechner; Atsuhiro Sugidachi; Paul Harrison Journal: Platelets Date: 2011-08-17 Impact factor: 3.862
Authors: Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Mark J Antonino; Cheryl Wei; Renli Teng; Lars Rasmussen; Robert F Storey; Tonny Nielsen; John W Eikelboom; Georges Sabe-Affaki; Steen Husted; Dean J Kereiakes; David Henderson; Dharmendra V Patel; Udaya S Tantry Journal: Circulation Date: 2010-03-01 Impact factor: 29.690
Authors: Dániel Aradi; András Komócsi; András Vorobcsuk; Orsolya Rideg; Margit Tokés-Füzesi; Tamás Magyarlaki; Iván Gábor Horváth; Victor L Serebruany Journal: Am Heart J Date: 2010-09 Impact factor: 4.749
Authors: Moritz Lenschow; Niklas von Spreckelsen; Sergej Telentschak; Christoph Kabbasch; Roland Goldbrunner; Stefan Grau Journal: Neurosurg Rev Date: 2022-04-29 Impact factor: 2.800
Authors: Jens Maybaum; Hans Henkes; Marta Aguilar-Pérez; Victoria Hellstern; Georg Alexander Gihr; Wolfgang Härtig; André Reisberg; Dirk Mucha; Marie-Sophie Schüngel; Richard Brill; Ulf Quäschling; Karl-Titus Hoffmann; Stefan Schob Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003